Press Release

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Limited, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition, set to close by June 2026, will significantly expand Aurobindo's portfolio of complex generic and non-opioid controlled substances and add a U.S.-based manufacturing facility. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate meaningful cost efficiencies and synergies, supporting sustainable long-term growth.